Suppression of dopamine-related side effects of morphine by aripiprazole, a dopamine system stabilizer

European Journal of Pharmacology

Volumn 600, Issue 1-3, 2008, Pages 105-109

  Narita, Minoru ^a   Takei, Daisuke ^a   Shiokawa, Mitsuru ^a,b   Tsurukawa, Yuri ^a   Matsushima, Yuki ^a   Nakamura, Atsushi ^a   Takagi, Shigemi ^a   Asato, Megumi ^a   Ikegami, Daigo ^a   Narita, Michiko ^a   Amano, Taku ^a,c   Niikura, Keiichi ^a   Hashimoto, Keisuke ^a   Kuzumaki, Naoko ^a   Suzuki, Tsutomu ^a  

^a HOSHI UNIVERSITY   (Japan)

^b ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Aripiprazole; Dependence; Dopamine; Morphine; Opioid

Indexed keywords

ARIPIPRAZOLE; DOPAMINE RECEPTOR BLOCKING AGENT; MORPHINE; PROCHLORPERAZINE;

ANIMAL EXPERIMENT; ARTICLE; CATALEPSY; DOPAMINE BRAIN LEVEL; DRUG MEGADOSE; INSTITUTE FOR CANCER RESEARCH MOUSE; LOCOMOTION; MALE; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; REWARD;

ANALGESICS, OPIOID; ANIMALS; ANTIPSYCHOTIC AGENTS; CATALEPSY; DOPAMINE; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERKINESIS; MALE; MICE; MICE, INBRED ICR; MORPHINE; NUCLEUS ACCUMBENS; PIPERAZINES; PROCHLORPERAZINE; QUINOLONES; REWARD; SEVERITY OF ILLNESS INDEX;

EID: 55949105784     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.10.030     Document Type: Article

References (21)

1. Aparasu R., McCoy R.A., Weber C., Mair D., and Parasuraman T.V. Opioid-induced emesis among hospitalized nonsurgical patients: effect on pain and quality of life. J. Pain Symp. Manag. 18 (1999) 280-288
2. Casey D.E. Acute Extrapyramidal Syndromes (1995), American Psychiatric Press, Inc., Washington DC
3. Costello D.J., and Borison H.L. Naloxone antagonizes narcotic self blockade of emesis in the cat. J. Pharmacol. Exp. Ther. 203 (1977) 222-230
4. Funada M., and Shippenberg T.S. Differential involvement of D1 and D2 dopamine receptors in the expression of morphine withdrawal signs in rats. Behav. Pharmacol. 7 (1996) 448-453
5. Gaudreau J.D., Gagnon P., Roy M.A., Harel F., and Tremblay A. Opioid medications and longitudinal risk of delirium in hospitalized cancer patients. Cancer 109 (2007) 2365-2373
6. Koob G.F., Sanna P.P., and Bloom F.E. Neuroscience of addiction. Neuron 21 (1998) 467-476
7. Li Z., Ichikawa J., Dai J., and Meltzer H.Y. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur. J. Pharmacol. 493 (2004) 75-83
8. McNicol E., Horowicz-Mehler N., Fisk R.A., Bennett K., Gialeli-Goudas M., Chew P.W., Lau J., and Carr D. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J. Pain 4 (2003) 231-256
9. Naber D., and Lambert M. Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism. Prog. Neuropsychopharmacol. Biol. Psych. 28 (2004) 1213-1219
10. Narita M., Takahashi Y., Takamori K., Funada M., Suzuki T., Misawa M., and Nagase H. Effects of kappa-agonist on the antinociception and locomotor enhancing action induced by morphine in mice. Jpn. J. Pharmacol. 62 (1993) 15-24
11. Narita M., Funada M., and Suzuki T. Regulations of opioid dependence by opioid receptor types. Pharmacol. Ther. 89 (2001) 1-15
12. Ohlsen R.I., and Pilowsky L.S. The place of partial agonism in psychiatry: recent developments. J. Psychopharmacol. 19 (2005) 408-413
13. Paxinos G., and Franklin K. The Mouse Brain in Stereotaxic Coordinates (1997), Academic Press
14. Ross D.D., and Alexander C.S. Management of common symptoms in terminally ill patients: Part II. Constipation, delirium and dyspnea. Am. Fam. Phys. 64 (2001) 1019-1026
15. Rubin A., and Winston J. The role of the vestibular apparatus in the production of nausea and vomiting following the administration of morphine to man; clinical and experimental data including the effects of dramamine and benzedrine. J. Clin. Invest. 29 (1950) 1261-1266
16. Shiokawa M., Narita M., Nakamura A., Kurokawa K., Inoue T., and Suzuki T. Usefulness of the dopamine system-stabilizer aripiprazole for reducing morphine-induced emesis. Eur. J. Pharmacol. 570 (2007) 108-110
17. Sipahimalani A., and Masand P.S. Olanzapine in the treatment of delirium. Psychosomatics 39 (1998) 422-430
18. Tonini M., Cipollina L., Poluzzi E., Crema F., Corazza G.R., and De Ponti F. Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment. Pharmacol. Ther. 19 (2004) 379-390
19. Trzepacz P.T. Is there a final common neural pathway in delirium? Focus on acetylcholine and dopamine. Semin. Clin. Neuropsychiatry 5 (2000) 132-148
20. WHO. Cancer Pain Relief. 2nd ed. (1996), World Health Organization, Geneva
21. Winans E. Aripiprazole. Am. J. Health-Syst. Pharm. 60 (2003) 2437-2445